vs
ACME UNITED CORP（ACU）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是ACME UNITED CORP的1.3倍（$69.8M vs $52.3M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 1.9%，领先382.2%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 13.8%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -2.9%）
埃克米联合公司（Acme United Corporation）是面向校园、家居、办公、五金及工业领域的切削工具、测量工具与安全防护用品供应商，行业历史悠久，其前身可追溯至1867年成立的合伙企业，1873年在康涅狄格州完成法人注册，目前在美国纽约泛欧美交所挂牌上市，股票代码为ACU。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
ACU vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.3倍
$52.3M
营收增速更快
RIGL
高出7.4%
13.8%
净利率更高
RIGL
高出382.2%
1.9%
两年增速更快
RIGL
近两年复合增速
-2.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $52.3M | $69.8M |
| 净利润 | $985.0K | $268.1M |
| 毛利率 | 39.7% | 91.5% |
| 营业利润率 | 3.3% | 33.2% |
| 净利率 | 1.9% | 384.0% |
| 营收同比 | 13.8% | 21.2% |
| 净利润同比 | -40.4% | 1769.2% |
| 每股收益（稀释后） | $0.24 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACURIGL
| Q1 26 | $52.3M | — | ||
| Q4 25 | $47.5M | $69.8M | ||
| Q3 25 | $49.1M | $69.5M | ||
| Q2 25 | $54.0M | $101.7M | ||
| Q1 25 | $46.0M | $53.3M | ||
| Q4 24 | $45.9M | $57.6M | ||
| Q3 24 | $48.2M | $55.3M | ||
| Q2 24 | $55.4M | $36.8M |
净利润ACURIGL
| Q1 26 | $985.0K | — | ||
| Q4 25 | $1.9M | $268.1M | ||
| Q3 25 | $1.9M | $27.9M | ||
| Q2 25 | $4.8M | $59.6M | ||
| Q1 25 | $1.7M | $11.4M | ||
| Q4 24 | $1.7M | $14.3M | ||
| Q3 24 | $2.2M | $12.4M | ||
| Q2 24 | $4.5M | $-1.0M |
毛利率ACURIGL
| Q1 26 | 39.7% | — | ||
| Q4 25 | 38.2% | 91.5% | ||
| Q3 25 | 39.1% | 93.2% | ||
| Q2 25 | 41.0% | 95.6% | ||
| Q1 25 | 39.0% | 91.7% | ||
| Q4 24 | 38.7% | 89.9% | ||
| Q3 24 | 38.5% | 85.5% | ||
| Q2 24 | 40.8% | 92.4% |
营业利润率ACURIGL
| Q1 26 | 3.3% | — | ||
| Q4 25 | 6.1% | 33.2% | ||
| Q3 25 | 6.1% | 40.9% | ||
| Q2 25 | 11.8% | 60.1% | ||
| Q1 25 | 5.3% | 23.9% | ||
| Q4 24 | 5.0% | 28.9% | ||
| Q3 24 | 6.1% | 25.4% | ||
| Q2 24 | 11.5% | 1.2% |
净利率ACURIGL
| Q1 26 | 1.9% | — | ||
| Q4 25 | 3.9% | 384.0% | ||
| Q3 25 | 3.9% | 40.2% | ||
| Q2 25 | 8.8% | 58.6% | ||
| Q1 25 | 3.6% | 21.5% | ||
| Q4 24 | 3.7% | 24.9% | ||
| Q3 24 | 4.6% | 22.5% | ||
| Q2 24 | 8.0% | -2.8% |
每股收益（稀释后）ACURIGL
| Q1 26 | $0.24 | — | ||
| Q4 25 | $0.46 | $14.11 | ||
| Q3 25 | $0.46 | $1.46 | ||
| Q2 25 | $1.16 | $3.28 | ||
| Q1 25 | $0.41 | $0.63 | ||
| Q4 24 | $0.43 | $0.82 | ||
| Q3 24 | $0.54 | $0.70 | ||
| Q2 24 | $1.09 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.2M | $155.0M |
| 总债务越低越好 | $33.0M | $52.5M |
| 股东权益账面价值 | $116.7M | $391.5M |
| 总资产 | $195.2M | $513.6M |
| 负债/权益比越低杠杆越低 | 0.28× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资ACURIGL
| Q1 26 | $4.2M | — | ||
| Q4 25 | $3.6M | $155.0M | ||
| Q3 25 | $5.1M | $137.1M | ||
| Q2 25 | $3.6M | $108.4M | ||
| Q1 25 | $3.4M | $77.1M | ||
| Q4 24 | $6.4M | $77.3M | ||
| Q3 24 | $5.7M | $61.1M | ||
| Q2 24 | $3.8M | $49.1M |
总债务ACURIGL
| Q1 26 | $33.0M | — | ||
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M |
股东权益ACURIGL
| Q1 26 | $116.7M | — | ||
| Q4 25 | $117.6M | $391.5M | ||
| Q3 25 | $115.8M | $117.6M | ||
| Q2 25 | $113.7M | $81.9M | ||
| Q1 25 | $108.3M | $18.6M | ||
| Q4 24 | $107.0M | $3.3M | ||
| Q3 24 | $106.3M | $-14.6M | ||
| Q2 24 | $104.0M | $-29.9M |
总资产ACURIGL
| Q1 26 | $195.2M | — | ||
| Q4 25 | $171.0M | $513.6M | ||
| Q3 25 | $173.0M | $242.5M | ||
| Q2 25 | $170.9M | $206.7M | ||
| Q1 25 | $163.0M | $176.0M | ||
| Q4 24 | $162.2M | $164.0M | ||
| Q3 24 | $165.5M | $139.4M | ||
| Q2 24 | $173.5M | $128.4M |
负债/权益比ACURIGL
| Q1 26 | 0.28× | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ACURIGL
| Q1 26 | — | — | ||
| Q4 25 | $8.2M | $22.0M | ||
| Q3 25 | $7.1M | $24.0M | ||
| Q2 25 | $6.3M | $30.5M | ||
| Q1 25 | $-3.3M | $-893.0K | ||
| Q4 24 | $6.4M | $14.5M | ||
| Q3 24 | $8.9M | $21.7M | ||
| Q2 24 | $6.9M | $302.0K |
自由现金流ACURIGL
| Q1 26 | — | — | ||
| Q4 25 | $7.3M | — | ||
| Q3 25 | $301.0K | — | ||
| Q2 25 | $4.7M | — | ||
| Q1 25 | $-4.7M | — | ||
| Q4 24 | $4.7M | — | ||
| Q3 24 | $7.5M | — | ||
| Q2 24 | $4.4M | — |
自由现金流率ACURIGL
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | -10.2% | — | ||
| Q4 24 | 10.2% | — | ||
| Q3 24 | 15.6% | — | ||
| Q2 24 | 8.0% | — |
资本支出强度ACURIGL
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | — | ||
| Q3 25 | 13.8% | — | ||
| Q2 25 | 3.0% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 4.5% | — |
现金转化率ACURIGL
| Q1 26 | — | — | ||
| Q4 25 | 4.34× | 0.08× | ||
| Q3 25 | 3.72× | 0.86× | ||
| Q2 25 | 1.33× | 0.51× | ||
| Q1 25 | -2.02× | -0.08× | ||
| Q4 24 | 3.73× | 1.01× | ||
| Q3 24 | 3.99× | 1.75× | ||
| Q2 24 | 1.55× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
